Mivebresib

• Description:

  Mivebresib (ABBV-075) is a potent and orally active bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM[1].

• Product Name Alternative:

  ABBV-075

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  Apoptosis; Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Mivebresib.html

• Purity:

  99.69

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O

• Molecular Formula:

  C22H19F2N3O4S

• Molecular Weight:

  459.47

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [1445993-26-9]